MaaT013 fecal microbiotherapy modulates key gastro-intestinal and immunological processes involved in GvHD pathogenesis in vitro and in vivo. (PubMed, Front Microbiol) - Sep 30, 2026 - "MaaT013 (Xervyteg®), a standardized allogeneic fecal microbiotherapy derived from pooled healthy human fecal microbiota, has demonstrated efficacy in mitigating steroid-refractory aGvHD in the Phase 2 HERACLES trial, and is currently being evaluated in the pivotal ARES trial in ruxolitinib-resistant aGvHD with gastrointestinal involvement. Finally, MaaT013 delayed the appearance of aGvHD symptoms in a specific-pathogen free xenogeneic mouse model of aGvHD. Together, these results provide exploratory, multi-model evidence of MaaT013's potential to mitigate aGvHD by restoring microbial diversity, gut integrity, and immune homeostasis."
Journal • Preclinical • Acute Graft versus Host Disease • Graft versus Host Disease • Immunology • Inflammation • Inflammatory Bowel Disease • Transplantation • IL10
|
|
Antoine Sabourin; Bastien Laperrousaz; Benoît Levast; Carole Schwintner; Cassandra Bompard; Charlotte Petitjean; Cyrielle Gasc; Emmanuel Prestat; Emmanuelle Godefroy; Ernst Holler; Julie Reygner; Margaux De Seilhac; Nathalie Corvaia; Robert R Jenq; Sophie Declomesnil
|